MD Newsline
In this episode of MD Newsline, Dr. Quentin Youmans, a heart failure cardiologist at Northwestern Medicine, explores the rapidly evolving landscape of advanced heart failure care. He shares insights into guideline-directed medical therapy, emerging device-based interventions, and the growing role of personalized medicine in improving outcomes for patients with complex cardiovascular disease. Dr. Youmans also addresses health disparities, access challenges, and the importance of multidisciplinary collaboration in modern cardiology. Episode Highlights Advances in Guideline-Directed Medical...
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Aruna Anupindi, a consultant clinical oncologist based in Oxford, UK, joins the podcast to discuss evolving trends in breast and prostate cancer care. Specializing in breast and urological cancers, Dr. Anupindi shares insights from her clinical practice, highlights key takeaways from recent oncology conferences, and reflects on the growing importance of early detection, personalized therapies, and quality of life in cancer treatment. She also addresses disparities in screening uptake, emerging treatment strategies aimed at reducing chemotherapy exposure,...
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies. She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also...
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Sherene Loi, a medical oncologist and laboratory head at the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses groundbreaking research published in Nature exploring how pregnancy and breastfeeding influence immune protection against triple-negative breast cancer. Dr. Loi shares insights into how reproductive history reshapes the immune system, particularly T cell activity, and how these findings may inform future prevention strategies, screening approaches, and immunotherapy development. Episode Highlights: The Immune System’s Role in...
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Joel Wright, a rheumatology fellow at UCLA, provides an in-depth, practical discussion on axial spondyloarthritis and related spondyloarthritides. Dr. Wright breaks down evolving disease definitions, diagnostic challenges, imaging interpretation, and modern treatment strategies, while emphasizing a holistic, patient-centered approach to care. The conversation highlights how early recognition and individualized therapy can significantly improve long-term outcomes. Episode Highlights Defining Axial vs. Peripheral Spondyloarthritis Dr. Wright explains the...
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Marianna Cortese, a medical doctor and epidemiologist at the Harvard T.H. Chan School of Public Health, shares groundbreaking research on the link between vitamin D, Epstein-Barr virus (EBV), and the risk of multiple sclerosis (MS). Her work, conducted within the U.S. military cohort, sheds new light on racial, genetic, and environmental factors influencing MS development and potential prevention strategies. Dr. Cortese discusses how vitamin D levels and immune response modulation play a role in MS prevention, and how EBV infection—now recognized as the...
info_outlineMD Newsline
In this episode of MD Newsline, patient advocate Tameka Carter shares her personal journey living with hidradenitis suppurativa (HS), a chronic, painful inflammatory skin condition often misdiagnosed for years. Tameka discusses the early signs of HS, the emotional and physical toll of delayed diagnosis, and the importance of finding a specialist who truly listens. She offers valuable insight into treatment decision-making, lifestyle changes, and the critical role of self-advocacy in managing a lifelong condition. Episode Highlights Early Symptoms and Delayed Diagnosis Tameka reflects on...
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Gloria Dalla Costa, a researcher at Harvard University, shares groundbreaking insights into the role of ultra-processed foods in multiple sclerosis (MS) progression. Drawing from her research on environmental and metabolic risk factors, Dr. Dalla Costa discusses how dietary habits may influence inflammation, disease activity, and long-term neurological outcomes in MS patients. Her work reveals compelling evidence that higher consumption of ultra-processed foods correlates with increased inflammatory markers, worsened MRI outcomes, and a greater risk of...
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Ahmed Abdelhak, Assistant Professor of Neurology at the University of California, San Francisco, explores the cutting-edge world of fluid biomarkers in multiple sclerosis (MS). With over a decade of experience as an MS clinical scientist, Dr. Abdelhak shares his expertise on the evolving role of biomarkers in understanding, predicting, and managing MS progression. He breaks down how markers like neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and chitinase (CHIT1/CHIT3) offer insights into the underlying neuroinflammatory and...
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Nilüfer Kale, Head of the Department of Neurology at Başakşehir Çam and Sakura City Hospital in Istanbul, Turkey, provides an in-depth look into optic neuritis, multiple sclerosis (MS), and related demyelinating disorders. She discusses the pathophysiology, diagnostic challenges, and treatment evolution of these conditions—offering valuable insights for clinicians managing autoimmune neuroinflammatory diseases. Dr. Kale also highlights the importance of accurate differential diagnosis, the role of neuroimaging and biomarkers, and how advancements in...
info_outlineIn this episode of MD Newsline, Dr. Shaina A. Rozell, a hematologist-oncologist at Affiliate Oncology in Chicago, Illinois, explores the rapidly advancing field of multiple myeloma treatment. She discusses how quadruplet therapies, MRD monitoring, and novel immunotherapies like bispecific antibodies and CAR-T are transforming outcomes for patients. Dr. Rozell also examines disparities in access to care, the growing role of community practices in clinical trials, and the balance between extending survival and preserving quality of life.
Episode Highlights1. The Rise of Quadruplet Therapy Dr. Rozell explains how treatment has evolved from triplet to quadruplet regimens, incorporating agents such as daratumumab and isatuximab. These combinations have led to higher sustained MRD negativity and longer progression-free survival, offering some patients an alternative to stem cell transplantation.
2. Redefining the Role of Stem Cell Transplant While autologous transplants remain a mainstay, Dr. Rozell notes that emerging immunotherapies may one day reduce their necessity. She compares the shift in multiple myeloma to the eventual phasing out of stem cell transplants in breast cancer.
3. CAR-T and Bispecific Antibodies Access and feasibility play major roles in therapy selection. Dr. Rozell contrasts CAR-T—limited to tertiary centers—with bispecifics, which can now be administered in some community practices. Collaboration between local clinics and academic centers remains crucial for expanding access.
4. Supportive Care and Toxicity Management Advances in bone protection, infection prevention, and supportive care bundles are improving patient quality of life. However, Dr. Rozell underscores the ongoing challenge of managing long-term toxicities like neuropathy and heart failure.
5. Genetic and Cytogenetic Factors Cytogenetic abnormalities such as 17p deletions continue to shape prognosis and treatment choice. Dr. Rozell highlights the need for consistent genetic testing and patient education to ensure optimal therapeutic decisions.
6. Clinical Trial Diversity and Representation Dr. Rozell advocates for greater minority participation in clinical research, emphasizing the importance of trust, communication, and representation among both patients and providers to ensure equitable advancement of care.
7. The Future of Myeloma Research Looking ahead, Dr. Rozell anticipates MRD will become a central endpoint in clinical trials. She envisions a future with more home-based treatments, enhanced telemedicine integration, and continued innovation in supportive care and survivorship strategies.
Key TakeawayDr. Shaina Rozell underscores the transformation of multiple myeloma treatment through quadruplet therapies and MRD-driven care. By combining innovation, equity, and collaboration between community and academic centers, the field is moving closer to more accessible, effective, and personalized care for all patients.
ResourcesWebsite: https://mdnewsline.com/
Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Shaina A. Rozell: Here
Hosted on Acast. See acast.com/privacy for more information.